Zentalis Pharmaceuticals (ZNTL) Enterprise Value (2020 - 2026)

Zentalis Pharmaceuticals' Enterprise Value history runs 8 years deep, the most recent figure standing at -$211.8 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 33.89% year-over-year to -$211.8 million; the TTM figure through Mar 2026 stood at -$211.8 million (up 33.89% YoY), while the FY2025 annual figure was -$245.9 million, down 363.29% from the prior year.
• Enterprise Value for Q1 2026 stood at -$211.8 million, up from -$245.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$27.9 million in Q4 2023, with the low at -$320.3 million in Q1 2025.
• The 5-year median for Enterprise Value is -$42.8 million (2022), against an average of -$97.3 million.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value soared 88.89% in 2022, then sank 751.5% in 2025.
• Zentalis Pharmaceuticals' Enterprise Value stood at -$42.8 million in 2022, then jumped by 34.81% to -$27.9 million in 2023, then tumbled by 90.02% to -$53.1 million in 2024, then sank by 363.29% to -$245.9 million in 2025, then climbed by 13.88% to -$211.8 million in 2026.
• Business Quant data shows ZNTL's Enterprise Value at -$211.8 million in Q1 2026, -$245.9 million in Q4 2025, and -$41.5 million in Q3 2025.